Literature DB >> 4325100

Herpes-like Epstein-Barr virus in leprosy.

P S Papageorgiou, C Sorokin, K Kouzoutzakoglou, P R Glade.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1971        PMID： 4325100     DOI： 10.1038/231047a0

Source DB:  PubMed          Journal:  Nature        ISSN： 0028-0836            Impact factor:   49.962


× No keyword cloud information.
  9 in total

1.  Antibodies to Epstein-Barr virus in patients with cryptococcosis.

Authors:  P H Levine; R D Diamond; J I Reisher
Journal:  J Clin Microbiol       Date:  1975-04       Impact factor: 5.948

2.  Host responses to Epstein-Barr virus and cytomegalovirus infection in leprosy.

Authors:  P S Papageorgiou; C F Sorokin; K Kouzoutzakoglou; R J Bonforte; P L Workman; P R Glade
Journal:  Infect Immun       Date:  1973-04       Impact factor: 3.441

3.  Epstein-Barr virus antibody in cases and contacts of infectious mononucleosis; a family study.

Authors:  F J Nye; H P Lambert
Journal:  J Hyg (Lond)       Date:  1973-03

4.  Epstein-Barr virus and inflammatory bowel disease.

Authors:  H W Grotsky; Y Hirshaut; C Sorokin; D Sachar; H D Janowitz; P R Glade
Journal:  Experientia       Date:  1971-12-15

5.  Antinuclear antibodies and elevated anti-Epstein-Barr virus titers in cancer patients.

Authors:  N K McCormick; K J McCormick; J J Trentin
Journal:  Infect Immun       Date:  1976-05       Impact factor: 3.441

6.  Virus antibody levels and delayed hypersensitivity in rheumatoid arthritis.

Authors:  P E Phillips; J Waxman; Y Hirshaut; M H Kaplan
Journal:  Ann Rheum Dis       Date:  1976-04       Impact factor: 19.103

7.  Clinical aspects of infection with the Epstein-Barr virus.

Authors:  R N Sutton
Journal:  J R Coll Physicians Lond       Date:  1975-01

Review 8.  CD4+ Cytotoxic T Cells Involved in the Development of EBV-Associated Diseases.

Authors:  Manuel Ruiz-Pablos
Journal:  Pathogens       Date:  2022-07-25

Review 9.  Amplification of autoimmune disease by infection.

Authors:  David N Posnett; Dmitry Yarilin
Journal:  Arthritis Res Ther       Date:  2005-02-10       Impact factor: 5.156
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.